Phase I Study to Assess the Effect of Trastuzumab Deruxtecan on QTc Interval and Pharmacokinetics in HER2-Expressing Metastatic or Unresectable Breast Cancer

December 10-14, 2019; San Antonio, Texas
In heavily pretreated patients with HER2-expressing breast cancer, trastuzumab deruxtecan did not result in clinically meaningful prolongation of QTc interval and was associated with a manageable safety profile and antitumor activity.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: December 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

In this commentary, experts look ahead to key studies being reported at SABCS 2022 and highlight the data they are most excited to see, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: December 5, 2022

Downloadable slideset on optimizing the personalized care of patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: December 5, 2022

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Expert commentary with Dr Charles Geyer on the essential need for BRCA testing in early breast cancer to guide adjuvant olaparib decisions, from Clinical Care Options (CCO) and ProCE

Charles E. Geyer, Jr., MD Released: November 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings